MRK Up More Than 7% on Improved Long-Term Prospects: Still a Sell?
View original at finance.yahoo.comMRK Up More Than 7% on Improved Long-Term Prospects: Still a Sell? Merck’s MRK stock has risen 7.4% in the past month. A key driver of the increase was better-than-expected fourth-quarter results and a more confident outlook for its future growth…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The $70 billion pipeline estimate is more than double the peak consensus sales estimate for Keytruda of $35 billion in 2028
80% confidenceMerck expects over $70 billion of potential non-risk-adjusted commercial opportunity for the current pipeline by the mid-2030s
80% confidenceShort-term investors may stay away from this stock but long-term investors may stay invested to see how it manages future product and pipeline growth
80% confidenceAdjusted earnings per share are expected to be between $5.00 and $5.15 in 2026
80% confidenceivonescimab has the potential to replace Keytruda as the next standard of care across multiple NSCLC settings
80% confidenceAnimal Health business sales expected to more than double by mid-2030s
80% confidenceGardasil sales are not expected to improve in 2026
80% confidenceGeneric competition for Januvia/Janumet, Bridion and Dificid expected to hurt revenues by approximately $2.5 billion in 2026
80% confidenceMerck expects revenues to be in the range of $65.5-$67.0 billion in 2026, representing year-over-year growth of 1% to 3%
80% confidenceMerck rated as Rank #4 (Sell) due to limited prospects for growth in the near term despite long-term potential
80% confidenceMerck expects Keytruda to achieve peak sales of $35 billion by 2028
80% confidenceThe estimate of $70 billion was $20 billion higher than what they expected just one year ago
80% confidence
Data points we hold from this source
| Merck & Co., Inc. · revenue | 16.40 billion_USD |